{"id":"f6015b144b7a","type":"article","url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","title":"Inclisiran als monotherapie verlaagt LDL-C met 47,5% in Chinese volwassenen — VICTORION-Mono","title_en":"Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.06.016","source_url":"https://doi.org/10.1016/j.jacl.2026.06.016","authors":["Yong Huo","Janna Sand Dejmek","Zuyi Yuan","Daoquan Peng","Jorge Mena-Madrazo","Karen X Liu","Mengli Zhang","Yuan Ji","Xiaochun Xing","Zhuhua Yao","Yuyang Liu","Weihong Jiang","Lingyan Bai"],"significance":5,"published":"2026-08-09","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The phase-3 VICTORION-Mono trial evaluated inclisiran monotherapy in 207 Chinese adults with elevated LDL-C and low-to-moderate ASCVD risk. At day 150, inclisiran reduced LDL-C by 47.5% compared with placebo, with sustained lipid-lowering effects and significant reductions in Lp(a) and ApoB through day 360. The treatment was well-tolerated, supporting inclisiran as a viable monotherapy option for dyslipidemia management in this population.","created":"2026-08-03T00:45:51Z","updated":"2026-08-10T10:36:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De fase-3 RCT VICTORION-Mono onderzocht de effectiviteit en veiligheid van inclisiran als monotherapie bij 207 Chinese volwassenen met verhoogd LDL-C en een laag tot matig ASCVD-risico. Na 150 dagen leidde inclisiran tot een significante LDL-C-daling van 47,5% ten opzichte van placebo, met aanhoudende effecten tot dag 360 en verbeteringen in Lp(a) en ApoB. Het profiel was veilig met voornamelijk milde bijwerkingen, wat inclisiran ondersteunt als een waardevolle optie voor lipidemanagement in deze populatie.","abstract_original":"BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in China. Elevated low-density lipoprotein cholesterol (LDL-C) is a major, modifiable cardiovascular disease and mortality risk factor, but many patients fail to achieve guideline-recommended lipid goals. Although inclisiran provides sustained and effective LDL-C reductions alone or when combined with lipid-lowering therapies (LLTs), its effectiveness as monotherapy has not been investigated in patients from China. OBJECTIVE: To evaluate the efficacy and safety of inclisiran monotherapy in Chinese adults with low/moderate ASCVD risk and elevated LDL-C not receiving LLT. METHODS: VICTORION-Mono China (NCT05888103) was a phase 3, multicenter, randomized trial, comprising a double-blind, placebo-controlled, 6-month treatment period, and a 6-month open-label extension period. The primary endpoint was the percentage change in LDL-C from baseline to Day 150. Other lipid biomarkers and safety were also assessed. RESULTS: In 207 randomized patients, inclisiran significantly reduced LDL-C vs placebo on Day 150 (least square mean [LSM] difference: -47.50%; P < .0001), with reductions sustained through Day 360. Furthermore, on Day 150, inclisiran induced a significant (P < .0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%; nonhigh-density lipoprotein cholesterol, -40.57%; apolipoprotein B, -36.84%). Inclisiran was well-tolerated; the most common drug-related treatment-emergent adverse events were mild hepatic enzyme elevations, injection-site reactions, and nausea. CONCLUSION: Inclisiran monotherapy provided sustained and effective LDL-C reductions with a favorable safety profile in Chinese adults with low/moderate ASCVD risk. These findings align with previous observations in statin-treated patients, supporting inclisiran monotherapy as a potential LDL-C-lowering option for Chinese patients."}